Welcome to our dedicated page for Myriad Genetics news (Ticker: $MYGN), a resource for investors and traders seeking the latest updates and insights on Myriad Genetics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Myriad Genetics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Myriad Genetics's position in the market.
Rhea-AI Summary
Myriad Genetics, Inc. (Nasdaq: MYGN) and Personalis, Inc. (Nasdaq: PSNL) have announced a collaboration to introduce the Personalis® ImmunoID NeXT platform to Myriad's pharmaceutical partners using their cancer tests. This collaboration aims to provide whole exome and whole transcriptome testing on patients' tumors, expanding Myriad's service offering. The ImmunoID NeXT platform is utilized by top global bio-pharma companies and offers high-quality exome/transcriptome assays for cancer FFPE samples.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.83%
Tags
-
Rhea-AI Summary
Myriad Genetics, Inc. (NASDAQ: MYGN) to participate in Stephens Annual Investment Conference for a fireside chat on November 15 at 2:00 p.m. ET. Live and archived webcast available on www.myriad.com
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.94%
Tags
-
Rhea-AI Summary
Myriad Genetics, Inc. (NASDAQ: MYGN) announced the pricing of an upsized underwritten public offering of 6,470,588 shares of its common stock at a public offering price of $17.00 per share for expected gross proceeds of approximately $110 million. The Company also granted the underwriters a 30-day option to purchase up to an additional 970,588 shares of its common stock at the public offering price. The offering is expected to close on November 13, 2023. The net proceeds will be used to repay outstanding loans, settle a class action, and for general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.94%
Tags
Rhea-AI Summary
Myriad Genetics, Inc. (NASDAQ: MYGN) announced a public offering of $100.0 million of common stock, with an option for underwriters to purchase an additional $15.0 million. The proceeds will be used to repay outstanding loans, settle a class action lawsuit, and for general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.94%
Tags
-
Rhea-AI Summary
Myriad Genetics, a leader in genetic testing and precision medicine, reported strong financial results for the third quarter of 2023. Testing volumes grew across various categories, including hereditary cancer, prenatal, and pharmacogenomics. Revenue increased by 23% year-over-year, reaching $191.9 million. The company also raised its 2023 revenue guidance to between $747 million and $753 million, representing 10% - 11% growth over 2022. Additionally, Myriad Genetics introduced its 2024 revenue guidance of between $815 million and $835 million, showing continued growth in the coming year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.69%
Tags
-
Rhea-AI Summary
Myriad Genetics, Inc. has appointed Sam Raha as Chief Operating Officer (COO), effective December 11, 2023. Raha brings over 25 years of experience in general management, commercial, and operations in the life sciences and molecular diagnostics field. As COO, he will oversee lab operations, customer service, and product development. Raha's appointment is expected to contribute to Myriad's long-term growth strategy and operational excellence.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.03%
Tags
Rhea-AI Summary
Myriad Genetics, Inc. will hold its third quarter earnings conference call on November 6, 2023 at 4:30 p.m. EDT. The company's quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company's performance for the third quarter 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.03%
Tags
-
Rhea-AI Summary
QIAGEN and Myriad Genetics have announced a new master collaboration agreement to develop companion diagnostic tests in the field of cancer. The partnership aims to deliver innovative services and products to pharmaceutical companies, enabling the development and commercialization of proprietary cancer tests for the U.S. clinical market, and providing distributable companion diagnostic test kits for the global market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.27%
Tags
-
News
Rhea-AI Summary
A survey by Myriad Genetics reveals that breast density and family health history are misunderstood breast cancer risk factors. 48% of women surveyed do not know what breast density is and 50% are unsure if it is related to breast cancer risk. Women with dense breast tissue are up to four times more likely to develop breast cancer. The FDA has updated mammography regulations requiring facilities to notify patients about breast density by September 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.47%
Tags
Rhea-AI Summary
Myriad Genetics announces survey results revealing breast density and family health history as misunderstood breast cancer risk factors. Women with dense breasts are up to four times more likely to develop breast cancer. FDA requires mammography facilities to notify patients about breast density. Genetic testing can provide personalized cancer risk assessment. Lisa Wade's experience highlights the importance of genetic testing in detecting hidden cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.2%
Tags
Myriad Genetics, Inc.
Nasdaq:MYGN
MYGN Rankings
MYGN Stock Data
2.30B
74.68M
2.01%
103.03%
6.3%
Pharmaceutical Preparation Manufacturing
Manufacturing
United States of America
SALT LAKE CITY
About MYGN
myriad genetics inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. myriad is focused on three strategic imperatives: maintaining leadership in an expanding hereditary cancer market, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. for more information on how myriad is making a difference, please visit the company's website: www.myriad.com.